Trial Protocol ID BGB-11417-201

Trial Description

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of
Bcl-2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Contact us regarding Clinical Trials at or call us at 877-664-7724


  • Mohit Narang, M.D.

Disease Types


  • BeiGene USA Inc. NCT ID

  • NCT05471843